Programming B Cells to Deliver Novel Therapies for Patients
Immusoft is the world leader in the development of B cells as biofactories for therapeutic protein delivery, a novel approach that we have pioneered. Our approach, called Immune System Programming (ISP™) entails collecting a type of the patient’s immune cells, called B cells. In response to immune stimulation, B cells can turn into biofactories (known as plasma cells), each of which manufactures and secretes thousands of antibodies per second. We harness this biofactory capability of the plasma cell by programming B cells to produce personalized protein therapeutics.
Once we have programmed the B cells we expand the number and differentiate into plasma cells that produce massive amounts of our therapeutic protein. Once in the clinic, we will then infuse the ISP™ programmed cells back into the same patient, where we expect they will take up residence and produce therapeutic proteins for extended periods of time.
This chart provides an overview of our ground breaking technology. Click below for a fuller explanation.
Sean Ainsworth is Immusoft’s Chief Executive Officer and Chairman of the Board. He has 20 years’ experience in pharmaceuticals and biotechnology. Previously, he founded and led RetroSense Therapeutics, a gene therapy company he advanced into human clinical trials and sold to Allergan in 2016 in a deal valued at up to $555 million.
Earlier, he was deeply involved in the launch of Compendia Bioscience, Inc., and GeneVivo, LLC. At both he assisted in developing business models, licensing technologies, building management teams, and securing capital and first customers. Life Technologies acquired Compendia BioScience in 2012.
Sean founded Ainsworth BioConsulting in 2004 to provide licensing, as well as strategic and business planning services to the life science and entrepreneurial community. His clients included large pharma, small biotechs, universities, CROs, and venture investment funds. He has worked with clients at all stages of development.
His other professional experience includes research at Medical Biology Institute (now Avanir Pharmaceuticals, developers of Abreva, the leading cold sore medication) in San Diego, Calif., intellectual property at Koyama and Associates in Tokyo, and international corporate development consulting at The Mattson Jack Group in St. Louis, Mo.
Sean earned an M.B.A. in strategy and finance from Washington University in St. Louis. He holds a B.S. in Microbiology from University of California, San Diego.
Robert Sikorski, M.D., Ph.D., is an experienced drug developer who currently serves as the Managing Director of Woodside Way Ventures, a firm that advances the clinical development of novel, lifesaving technologies.
Prior to his current role, Dr. Sikorski served as the Chief Medical Officer of FivePrime Therapeutics, a public biotechnology company that was acquired by Amgen. He led the development of FivePrime’s biologics pipeline that spanned preclinical discovery through proof of concept to pivotal registration trials. During his tenure at the company, FivePrime grew from a market cap of $150 MM to $1.5 B.
Previously, Dr. Sikorski led an early-stage clinical development group at Medimmune and then AstraZeneca that advanced six novel molecules into clinical trials. He played a leading role in building Medimmune’s oncology portfolio through partnering and acquisition efforts. Before joining Medimmune, he led late-stage clinical development and post marketing efforts for several commercial drugs and drug candidates at Amgen. His leadership in the development of Vectibix resulted in the drug’s global approval with a first-in-class companion diagnostic based on tumor genotype.
Dr. Sikorski began his career as a Howard Hughes Research Fellow and Visiting Scientist at the National Cancer Institute and the National Human Genome Research Institute in the laboratory of Nobel Laureate Harold Varmus. Dr. Sikorski received a combined M.D. and Ph.D. from The Johns Hopkins University School of Medicine through a Medical Scientist Training Program scholarship. He completed his residency at Massachusetts General Hospital and an Oncology fellowship at The Johns Hopkins Oncology Center and has been board certified in both Medical Oncology and Internal Medicine. He is a former editor of the journal Science and the Journal of the American Medical Association.
Dr. Sikorski resides with his wife and four children in Woodside, California.
Dr. Robert Hayes is the Chief Scientific Officer at Immusoft, where he oversees Immusoft’s preclinical research and spearheads the near-term advancement of ISP-001 for the treatment of Mucopolysaccharidosis type I (MPS I) into a clinical study, and additional Immune System Programming (ISP™) candidates towards clinical development.
With nearly two decades of biologics discovery and development experience, Dr. Hayes has a proven track record for building teams around new scientific concepts and technologies, including cell therapeutics, transposon systems, cancer vaccines, and bispecific monoclonal antibodies. He also has significant experience in forming partnerships to advance the development and application of novel therapeutic platforms.
Dr. Hayes obtained his Ph.D. in Biochemistry at Imperial College London as a Royal College of Science Scholar. He was awarded a Royal Society University Fellowship for the work contained in his thesis and spent three years studying protein biochemistry at University California, Berkeley. He then joined a start-up computational biology company called Xencor located in Pasadena, California where he helped establish their “Antibodies by Design” technology. Xencor has since collaborated with many of the top pharmaceutics companies to bring improved antibodies to the clinic.
After six years at Xencor, Dr. Hayes joined Janssen BioTherapeutics (Johnson & Johnson) where he co-founded and developed the vision and strategy for Centyrex, a stand-alone Janssen R&D biotechnology company that developed alternative scaffolds with applications beyond traditional protein therapeutics. In 2014, he became Head of Biologics at Amgen, responsible for leadership, operational and strategic management of all aspects of biologics preclinical discovery, including bioreagent generation, large molecule lead identification, biologics optimization, and transition into preclinical development and manufacturing.
David Lowenschuss has over 25 years of experience working in the biotech and life science industry. He has worked in a number of different roles at large and small pharmaceutical and biotech companies, including Pfizer Inc. and Esperion Therapeutics, Inc where he was involved in a number of licensing and M/A transactions. Mr. Lowenschuss is a Board Member of Mekanistic Therapeutics LLC a start-up oncology company. Mr. Lowenschuss also co-founded and served as a founding board member of Gemphire Therapeutics, Inc. (NASDAQ: GEMP). Mr. Lowenschuss also co-founded Michigan Life Ventures, LLC. He holds a J.D. from George Washington University and an M.U.P. and B.A. from the University of Michigan.
R. Scott McIvor, Ph.D., Chief Development Officer at Immusoft, is Professor of Genetics, Cell Biology and Development at the University of Minnesota.
Dr. McIvor graduated with degrees in Cell and Molecular Biology, and Pathobiology from the University of Washington and obtained his Ph.D. in Microbiology from the University of Minnesota in 1982. He was a postdoctoral fellow first at the University of California, San Francisco, and then at Genentech, Inc., in South San Francisco, California, where he conducted some of the earliest work on gene transfer into animal tissues in vivo.
He has been at the University of Minnesota since 1986, where he initially was a member of the Department of Laboratory Medicine and Pathology and the University of Minnesota’s Institute of Human Genetics, where he served as Director of the Gene Therapy Program.
He is a two-time former member of the National Institutes of Health (NIH) Recombinant DNA Advisory Committee (RAC) has served extensively on NIH study sections and the Scientific Advisory Board of the NIH National Gene Vector Laboratories. He is currently a member of the Gene Therapy Resource Program Steering Committee for the National Heart, Lung and Blood Institute, and serves on the Editorial Board for Molecular Therapy. His research has been primarily in the area of human gene therapy, where he has extensive experience developing both viral and non-viral vectors for the treatment of genetic diseases and cancer.
SEATTLE–(BUSINESS WIRE)– Immusoft, a clinical-stage cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that it has successfully closed a license with the Regents of the University of Minnesota for the exclusive, worldwide rights to intellectual property (IP) for…
San Francisco, CA – (BUSINESS WIRE) – January 26, 2023 — Immusoft of CA, a wholly owned subsidiary of Immusoft Corporation (“Immusoft”), a clinical-stage cell therapy company dedicated to improving the lives of patients with rare or genetic diseases, announced today that the California Institute…
SEATTLE–(BUSINESS WIRE)–Immusoft, a clinical-stage cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for ISP-001 in the treatment of MPS I. The open…
